Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2007
10/18/2007US20070244047 Albumin fusion proteins
10/18/2007US20070244046 Identification and characterization of cancer stem cells and methods of use
10/18/2007US20070244045 Treatment of Acute Respiratory Distress Syndrome
10/18/2007US20070244044 Antimicrobial Peptides
10/18/2007US20070244042 Anti-cancer agents and/or transforming growth factor beta (TGF-beta or TGF beta ) antagonists; comprising a therapeutically effective amount of soluble type II receptor (sRII) and a soluble type III receptor (sRIII)
10/18/2007US20070244040 polypeptides and carriers, used for inducing and/or enhancing apoptosis, as well as for the treatment of cancer
10/18/2007US20070244039 Therapeutic agent composition and method of use
10/18/2007US20070244038 Methods for treating lymphocyte-associated disorders by modulation of siglec activity
10/18/2007US20070244037 Human Chemokine HCC-1 Polypeptides To Improve Stem Cell Transplantation
10/18/2007US20070244036 Mixture comprising recombinant blood coagulation factor for use in treatment and prevention of hemophila
10/18/2007US20070244035 Novel co-modulators of nuclear receptors and methods of detecting and treating steroid hormone-dependent diseases using same
10/18/2007US20070244034 GLP-1 pharmaceutical compositions
10/18/2007US20070244033 Methods of identifying compounds that modulate il-4 receptor-mediated ige synthesis utilizing a c-myc protein
10/18/2007US20070244032 Cancer Cell Targeting Gene Delivery Method
10/18/2007US20070243588 Blood coagulation factor; nucleotide sequence encodes polypeptide; amino acid sequence differs in 1-15 amino acid residues and comprises an introduced in vivo N-glycosylation site; substitution V253N; coagulation related disorders
10/18/2007US20070243577 Method for the detection of apoptosis by determining apoptosis-specific markers released into an extracellular medium through cellular release mechanisms
10/18/2007US20070243570 Apoptosis Inducer for Cancer Cell
10/18/2007US20070243567 Beta cell mimicking control algorithm for artificial pancreas
10/18/2007US20070243524 sequences from the Core/E1 region of HCV type 3; detection of HCV infection
10/18/2007US20070243266 N-[1(R)-(3H-imidazo[4,5-b]pyridin-2-yl)ethyl]-2-fluoro-4-methyl-3-oxo-4-aza-5 alpha -androst-1-en-17 beta -carboxamide; osteoporosis, periodontal disease, bone fracture, frailty, sarcopenia, depression, sexual dysfunction, and cognitive decline; tissue-selective androgen receptor modulators(SARM)
10/18/2007US20070243262 Stable S-nitrosothiol formulations
10/18/2007US20070243260 Treatment of Childhood Asthma
10/18/2007US20070243259 Nanoparticles for protein/peptide delivery and delivery means
10/18/2007US20070243258 Method and apparatus for forming crosslinked chromonic nanoparticles
10/18/2007US20070243255 Multifunctional supramolecular hydrogels as biomaterials
10/18/2007US20070243247 Dosage Form Containing The Active Ingredient Cholylsarcosine
10/18/2007US20070243226 Growth factor complex
10/18/2007US20070243224 Methods and compositions for treatment of lesioned sites of body vessels
10/18/2007US20070243214 Genes and proteins associated with angiogenesis and uses thereof
10/18/2007US20070243203 HIV polypeptide and polynucleotide fusions of Gag, Pol and Nef; AIDS; purifying the fusion polypeptide; carboxyamidation
10/18/2007US20070243192 Growth hormone receptor antagonist cancer treatment
10/18/2007US20070243190 Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis
10/18/2007US20070243185 Suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin; containing polypeptide with an aggregation inhibitor selected from the group consisting of L-arginine and L-cysteine.
10/18/2007US20070243183 Use of factor VIIa or factor VIIa equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage
10/18/2007US20070243182 Use of Carboxypeptidease G for Combating Antifolate Toxicity
10/18/2007US20070243181 Irak1c Splice Variant And Its Use
10/18/2007US20070243175 Methods and compositions for regenerating tissue
10/18/2007US20070243174 Methods and compositions for directing stem cells to the liver
10/18/2007US20070243173 Methods and compositions for directing stem cells to the heart
10/18/2007US20070243169 exposing an amino acid sequence comprising at least a portion of purified full-length encephalomyocarditis virus (EMCV) to at least one cell in an amount effective to inhibit Ran activity in the targeted cell and evaluating Ran protein activity in the cell
10/18/2007US20070243167 Novel Herpes Simplex Viruses
10/18/2007US20070243166 Hepatitis C Inhibitor Compounds
10/18/2007US20070243165 Granulocyte colony stimulating factor obtained from eggs laid by transgenic avians having newly described G-CSF glycosylation patterns; gene expression of exogenous proteins
10/18/2007US20070243164 Treating Skin Cancer
10/18/2007US20070243163 Respiratory tract delivery of interferon-tau
10/18/2007US20070243162 Labeled monoclonal antibody binds Kaposi's sarcoma-associated herpesvirus (KSHV); use in diagnosis and prognosis
10/18/2007US20070243161 Epigenetic modification of the loci for CAMTA1 and/or FOXP3 as a marker for cancer treatment
10/18/2007US20070243160 Remedies for nerve damages
10/18/2007US20070243156 Synthesis and utilization of peptide mimetics in drug discovery and medicine
10/18/2007US20070243135 Method of treating fetal growth retardation and placental ischaemia and insufficiency
10/18/2007US20070243132 Transdermal delivery of pharmaceutical agents
10/18/2007US20070243130 Biopolymer system for tissue sealing
10/18/2007DE202007008905U1 Zusammensetzung auf Basis eines Extraktes von Aloysia Triphylla Composition based on an extract of Aloysia Triphylla
10/18/2007DE102006018080A1 Lysobactinamide Lysobactinamide
10/18/2007CA2649364A1 The homeobox transcription factor bsx and uses thereof for treating diseases, in particular obesity
10/18/2007CA2649003A1 Livestock management for improved reproductive efficiency
10/18/2007CA2648675A1 Mature dendritic cell compositions and methods for culturing same
10/18/2007CA2648403A1 Soluble virus-specific t-cell receptor compositions
10/18/2007CA2648313A1 Calcium phosphate complex in acid containing chewing gum
10/18/2007CA2647907A1 Use of tm-601 for the diagnosis and treatment of tumors
10/18/2007CA2647271A1 Binder for c-reactive protein
10/18/2007CA2647246A1 Stimulation of neuron regeneration by secretory leukocyte protease inhibitor
10/18/2007CA2638864A1 Truncated il-17ra soluble receptor and methods of using in inflammation
10/18/2007CA2634465A1 Development of novel antibiotic alternatives
10/17/2007EP1845108A2 Monoclonal antibodies to purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
10/17/2007EP1845107A2 RGD-enriched gelatine-like proteins with enhanced cell binding
10/17/2007EP1845106A1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction
10/17/2007EP1845105A1 Modified exendins and uses thereof
10/17/2007EP1845104A1 Par-2 agonist
10/17/2007EP1845089A1 Novel lactams and uses thereof
10/17/2007EP1844798A1 Implantable putty material
10/17/2007EP1844787A1 Drugs for nerve cell regeneration
10/17/2007EP1844767A2 Epoxide hydrolase complexes and methods therewith
10/17/2007EP1844763A1 Percutaneously absorbable preparation, percutaneously absorbable preparation holding sheet, and percutaneously absorbable preparation holding equipment
10/17/2007EP1844734A2 Combination drug therapy for reducing scar tissue formation
10/17/2007EP1844158A2 Biomarker for inflammatory bowel disease
10/17/2007EP1844070A1 Peptides with neuropeptide-2 receptor (y2r) agonist activity
10/17/2007EP1844069A1 Molecules and chimeric molecules thereof
10/17/2007EP1844067A2 Novel peptides which interact with anti-apoptotic members of the family of bcl-2 proteins and use thereof
10/17/2007EP1844066A1 Motif of beclin protein which interacts with anti-apoptotic members of the family of bcl-2 proteins and use thereof
10/17/2007EP1843791A1 Treatment of degenerative diseases with the x-linked inhibitor of apoptosis
10/17/2007EP1843789A2 Compositions and methods for treating fibrotic disorders
10/17/2007EP1843788A2 Glp-1 agonists, compositions, methods and uses
10/17/2007EP1843784A2 Identification of phospholipase a2 as target in cancer treatment, with special emphasis on colorectal cancer and its mechanism of action
10/17/2007EP1843783A2 Control of drug release by transient modification of local microenvironments
10/17/2007EP1843782A1 Method and use of interferon compositions for the treatment of avian influenza
10/17/2007EP1843781A1 Composition for prevention, treatment and diagnosis of chronic inflammatory airway diseases
10/17/2007EP1843780A1 A method of treatment
10/17/2007EP1843779A2 Compositions containing the anti-angiogenic phscn-peptide
10/17/2007EP1843778A1 Compositions comprising epigallocatechin gallate and protein hydrolysate
10/17/2007EP1843777A2 HIV-1 gp41 FUSION PEPTIDES FOR IMMUNOMODULATION
10/17/2007EP1843776A2 Purified amphilic peptide compositions and uses thereof
10/17/2007EP1843773A1 Method and composition for treatment of neoplasms
10/17/2007EP1843753A2 Compositions for freeze-drying proteins
10/17/2007EP1843749A1 Controlled release compositions for interferon based on pegt/pbt block copolymers
10/17/2007EP1843746A1 Somatostatin analogue formulations
10/17/2007EP1699398A4 Enhancement of immune responses
10/17/2007EP1583548A4 Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
10/17/2007EP1541589B1 Fused protein with the function of both thrombolysis and anticoagulation and the use of it
10/17/2007EP1427758B1 Compositions and methods of treating diabetes
1 ... 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 ... 3163